​Novo Shares Drop Most In Two Years On “Disappointing Ozempic & Wegovy Misses” – Tyler Durden

Novo Shares Drop Most In Two Years On “Disappointing Ozempic & Wegovy Misses” Novo Nordisk shares in Copenhagen fell 7.7%, marking the steepest intraday plunge in two years. The Danish pharmaceutical giant delivered underwhelming second-quarter sales for its Wegovy (semaglutide) blockbuster anti-obesity drug. Shares are testing key support.  Wegovy’s second-quarter sales were 11.7 billion Danish kroner ($1.7 billion), while the Wall Street analyst estimate tracked by Bloomberg was about 13.66 billion kroner.  During an earnings call, CFO Karsten Knudsen told investors that revenue from the anti-obesity drug was pressured by higher-than-expected price concessions to US pharmacy benefits managers, calling it a…  — Continue at ZeroHedge News : Read More